CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients - Wikidata - wikimedia - TriplyDB

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

http://www.wikidata.org/entity/Q35588533

about

The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Application of IL-2 therapy to target T regulatory cell function Ubiquitin-dependent regulation of Foxp3 and Treg function Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer The role of regulatory T cells in cancer immunology Innate and adaptive immune cells in the tumor microenvironment Treg functional stability and its responsiveness to the microenvironment Targeting the innate immune system as immunotherapy for acute myeloid leukemia Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Microenvironmental regulation of tumor progression and metastasis Reciprocal relationship of T regulatory cells and monocytic myeloid-derived suppressor cells in LP-BM5 murine retrovirus-induced immunodeficiency Rational combinations of immunotherapeutics that target discrete pathways.B cells inhibit the antitumor immunity against an established murine fibrosarcoma Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Stromal reengineering to treat pancreas cancer Targeting regulatory T cells to improve vaccine immunogenicity in early life.The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies Development of individualized anti-metastasis strategies by engineering nanomedicines Regulatory T Cells Modulate DNA Vaccine Immunogenicity at Early Time via Functional CD4(+) T Cells and Antigen Duration.Immunotherapy in pediatric malignancies: current status and future perspectives Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial The immune system and inflammation in breast cancer.Transforming Cancer Prevention through Precision Medicine and Immune-oncology.How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development STIM1 and STIM2-mediated Ca(2+) influx regulates antitumour immunity by CD8(+) T cells Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma Harnessing the immune system for the treatment of breast cancer.CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.Induced regulatory T cells in inhibitory microenvironments created by cancer.Overcoming tumor-mediated immunosuppression.

P2860

Q21131158-787B6CD2-7E2D-432A-A97E-6A37E19667A5 Q26742012-798189E1-711A-468F-BCCB-8C966FE6772A Q26779184-B6C1BFE9-3D9D-4F4A-A9D5-AE27E6CFFB40 Q26827327-BB60617D-0CE6-4C82-8709-81A395F81E7E Q26863525-C0E93FB2-9117-40BB-8982-6AA9166717F5 Q26996829-68880678-0300-4CC8-9E48-9963E2960F48 Q27006663-BD25566F-C862-4350-8F89-5B1667F63D97 Q27008342-1EC7C066-324F-4504-83A1-6064966962D6 Q27008946-664A1EDD-BD5F-457A-8AD0-7284BCEBD251 Q27015876-9C3ED0AE-A207-4D36-9A75-8E48C17F1D63 Q27021570-34990C03-F65E-4E07-81C9-16D856D790FC Q29615504-2167F337-99ED-4F61-BB62-09193D66C110 Q33573202-8102BF78-1BBD-4F0E-9017-D7C56DFB2DAF Q33606144-B3BDDCAC-D2AB-46FE-953F-2AA4A59C3EB5 Q33684762-B705B375-89FE-4F6C-9447-147E4E6C713E Q33705698-FC2960A4-B184-4A1A-A43F-C7EF935F102B Q33707098-36789C64-52BB-45F6-8F31-8F30956EE76A Q33827708-DE47C275-057A-412D-A551-FDDD6C159262 Q34164169-9F0AD4A5-F4B2-4450-9991-07F3D0F3A9BF Q35538728-5AA93022-C604-4D89-8F6A-87C9489C3EF3 Q35967474-41BDEA49-0968-47AF-B47A-464F88F79ED6 Q36102001-EFBD86EB-7CBC-45E3-8C80-3C8D20195093 Q36691818-8AD8F096-2CEC-490C-92CA-18B064290878 Q37017190-6D40208F-0B47-4AF8-A5E0-99C9CD7178E5 Q37024271-865AC011-AC7D-4D18-9843-BAF88BE2CC3A Q37033451-E0A3D6EA-BC17-4F82-9A9B-EEA1FF998BE6 Q37114360-EDA34FC1-62EC-484A-9C11-7840F7A62022 Q37199750-9362B44E-43E7-43E3-B62B-4733ECC43356 Q37236886-38D4F122-23EC-478C-9953-EA99B206FD07 Q37276644-4603BD8A-0C70-4B50-AABC-6EFF8AD3A050 Q37437275-3A40DD96-8E97-436A-AB4B-7B34ACB3D4B2 Q37476039-D25F2328-D5F7-4874-BDFF-37A5549C7EFA Q37483117-7CCEC3E0-704D-4732-8D61-27FF64DE0A4A Q37542092-0F54F23D-A0D8-4D55-9F58-996B79EEE6CA Q37557653-73864C14-814C-4724-BCDD-9120E5E2D304 Q37670024-05B6102F-1237-4490-B2E6-92C868CB1CCA Q38111620-7E044FC2-8D7D-4AD8-9DE7-61847093DAA1 Q38198735-7E3F34F1-0627-4FB9-8B70-B6C0381BE627 Q38220701-DEF7914D-BAA7-459C-89F6-28D890F3D568 Q38262255-4443C972-3C7A-4F67-821E-98B7BC69D349

P2860

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

http://www.wikidata.org/entity/Q35588533

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@ast

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@en

type

label

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@ast

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@en

prefLabel

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@ast

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@en

P1433

Q35588533-3C464AD4-5B78-4A6E-A23C-8F326628E1F5

P1476

Q35588533-0C247E96-55E3-4A78-9F87-8806DE7BCD14

P2093

Q35588533-054C22AA-85C4-4193-A909-1BF1DFCA3305

Q35588533-1701E99C-A734-4DA7-B9BB-EFD9D1F497B7

Q35588533-17C6FE00-7BC7-4362-A6B6-94DAE4926C0C

Q35588533-1A7B3683-B1AB-4740-9F8F-A89640723F0C

Q35588533-1F3DABE1-851A-418F-8D53-EDDB5597D726

Q35588533-37E27785-6CAD-43F3-8705-37C677618531

Q35588533-4C772BBF-EC23-4429-A2A8-842E562A745A

Q35588533-5578A338-2135-4A39-9AC8-7C342FD77003

Q35588533-6B9E59DE-3695-4FA1-A71A-E10C2536ED49

Q35588533-794033A4-8BEC-4F85-8FEF-FD55BA9FFE1A

P2860

Q35588533-02CA8EC2-A3AF-4A3B-8F8C-6C70BB185151

Q35588533-07797902-0BC9-4705-9DE4-17E19A80206F

Q35588533-12FA7AC7-FAF1-41A3-BB52-B410B1A7D954

Q35588533-17AE5DBF-8A03-4F8F-8A69-EA62E362187C

Q35588533-1A0B3E08-019E-481E-9865-CAF24740064E

Q35588533-1AFCBCDF-4043-4951-AA86-F51F2CEF2F84

Q35588533-204B3318-99C6-48BF-8CBF-0281CA760797

Q35588533-20589E68-21F9-4A2F-95D9-8B0D54356001

Q35588533-2A371555-AE54-4139-9EC3-59A9A61DCDE3

Q35588533-2EAF6E22-3264-45F6-8D44-2580B9C650E1

P304

Q35588533-7031990A-4F13-46D0-8381-BF239C702C6F

P31

Q35588533-D5CE288A-E09B-45DD-AB8B-0A469F94317F

P356

Q35588533-EF4D45C8-37D7-4D7E-AF8C-A7BD840ECB2F

P407

Q35588533-8B966294-2725-4423-A028-071994C61898

P433

Q35588533-66FB2F22-6824-4E2C-975B-47DFB8FD4D8B

P478

Q35588533-7D4FCF20-B334-4964-8F73-8C31AD0B52CC

P50

Q35588533-3866F358-F4CC-4FA7-9AA7-182DF9546CF7

P577

Q35588533-1E7D2189-A793-4EEB-AA7D-AA87D8130F84

P698

Q35588533-B798E95F-3956-41E6-9467-9B83873E6FE1

P921

Q35588533-1B94E54D-1685-4100-9063-0560A27C3520

P932

Q35588533-192DB41F-FD6C-43F6-9831-09B295C68D7E

P356

SCITRANSLMED.3003330

P1433

Science Translational Medicine

P1476

CD25 blockade depletes and sel ...... munotherapy in cancer patients

@en

P2093

Adri Recio

http://www.w3.org/2001/XMLSchema#string

Andrew J Rech

http://www.w3.org/2001/XMLSchema#string

Angela DeMichele

http://www.w3.org/2001/XMLSchema#string

Carol K Tweed

http://www.w3.org/2001/XMLSchema#string

Charles H Pletcher

http://www.w3.org/2001/XMLSchema#string

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

James L Riley

http://www.w3.org/2001/XMLSchema#string

Jennifer A Trosko

http://www.w3.org/2001/XMLSchema#string

Kevin R Fox

http://www.w3.org/2001/XMLSchema#string

Leah I Leinbach

http://www.w3.org/2001/XMLSchema#string

P2860

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells

Mechanisms of foxp3+ T regulatory cell-mediated suppression

Regulatory T cells and immune tolerance

Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

P304

134ra62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3003330

http://www.w3.org/2001/XMLSchema#string

P407

P433

134

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Susan M Domchek

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22593175

http://www.w3.org/2001/XMLSchema#string

P921

P932

4425934

http://www.w3.org/2001/XMLSchema#string